Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dinoprostone Clear all
Completed Phase 4 Interventional

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

NCT00347503
View directory record Official record
Conditions
Cataract
Interventions
ketorolac 0.4%, bromfenac 0.09%
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2007 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

NCT02078102
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions
Meloxicam, Filgrastim
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 8, 2026, 11:55 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

NCT02354417
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Biological: ProHema-CB
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 8, 2026, 11:55 AM EDT
Recruiting Phase 2 Interventional

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

NCT06557733
View directory record Official record
Conditions
Colorectal Carcinoma, Familial Adenomatous Polyposis
Interventions
Biopsy Procedure, Biospecimen Collection, EP2/EP4 Antagonist TPST-1495, Esophagogastroduodenoscopy, Gastrointestinal Endoscopy, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Rochester, Minnesota • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

NCT01127581
View directory record Official record
Conditions
Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor
Interventions
MVI 200, Dinoprostone Vaginal Insert (DVI)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Not applicable Interventional Results available

Comparison of Pre-Induction Cervical Ripening

NCT01390233
View directory record Official record
Conditions
Failed Labour
Interventions
Prepidil Gel, Urinary Balloon Catheter, Combined Urinary Catheter & Prepidil Gel
Drug · Device · Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 8, 2026, 11:55 AM EDT
Terminated No phase listed Observational

The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism

NCT01008592
View directory record Official record
Conditions
Rhinitis, Urticaria
Interventions
levocetirizine or placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 8, 2026, 11:55 AM EDT
Withdrawn No phase listed Observational

Prostaglandin E2 as a Critical Mediator of Sex Disparities in Asthma

NCT03825302
View directory record Official record
Conditions
Asthma
Interventions
Methacholine challenge, Mannitol challenge
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

NCT04344795
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
Interventions
TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor

NCT00308711
View directory record Official record
Conditions
Cervical Ripening, Labor, Induced
Interventions
Misoprostol vaginal insert 100 mcg, Misoprostol vaginal insert 50 mcg, Dinoprostone vaginal insert (Cervidil)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

NCT01527838
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions
Single FT1050 treated UCB unit
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 2 Interventional

Celebrex for Pain Relief After Oral Surgery

NCT00006299
View directory record Official record
Conditions
Facial Pain
Interventions
Celebrex
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Eating for Colon Cancer Prevention

NCT00475722
View directory record Official record
Conditions
Colon Cancer
Interventions
1 Healthy Eating, 2 Mediterranean
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 8, 2026, 11:55 AM EDT
Terminated Phase 1 Interventional Results available

A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders

NCT02354443
View directory record Official record
Conditions
Metabolic Disorders
Interventions
ProHema-CB Transplant
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 4 Interventional Results available

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Not applicable Interventional Results available

Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening

NCT03111316
View directory record Official record
Conditions
Cervical Ripening, Induction of Labor
Interventions
Cervidil 10 MG Vaginal Insert, Foley Catheter
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04505566
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers

NCT01796951
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking
Interventions
Aspirin 325 mg daily, Celecoxib 200 mg BID
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
35 Years to 90 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Foley Catheter Versus Cervidil for Induction of Labor at Term

NCT01402050
View directory record Official record
Conditions
Labor Induction
Interventions
CERVIDIL (Dinoprostone), FOLEY BALLOON
Drug · Device
Lead sponsor
Pediatrix
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Mesa, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 8, 2026, 11:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening and Risk Factors of Colon Neoplasia

NCT01647776
View directory record Official record
Conditions
Colon Cancer
Interventions
Stool DNA Test, biopsies of rectal and colon mucosa, Questionnaires
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
30 Years to 80 Years
Enrollment
3,315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects

NCT00469690
View directory record Official record
Conditions
Cataract
Interventions
Acular, Xibrom
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Not applicable Interventional

Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity

NCT00496548
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fecal calprotectin, Urinary PGE-M Level
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 8, 2026, 11:55 AM EDT
Completed Phase 1 Interventional

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

NCT03758625
View directory record Official record
Conditions
HIV Infections
Interventions
a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigen
Biological
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 8, 2026, 11:55 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening

NCT03806231
View directory record Official record
Conditions
Induction of Labor Affected Fetus / Newborn
Interventions
Outpatient Dinoprostone 10mg, Inpatient Dinoprostone 10 mg
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St. George, Utah
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 8, 2026, 11:55 AM EDT